Let's Do the Numbers:
Ahead of the company's earnings announcement, analysts are expecting a positive EPS reading of 90 cents per share and revenues of $2.01 billion. We'll have to wait for Tuesday to see if Stryker has accomplished the estimated 111% rise in EPS and 114% increase in revenues on a year-over-year basis.Here's how the company's reported EPS has stacked up against analyst estimates in the past:
Quarter | Q1 | Q4 | Q3 | Q2 |
EPS Estimate | 89 cents | 90 cents | 77 cents | 80 cents |
EPS Actual | 90 cents | 93 cents | 80 cents | 80 cents |
Stock Performance:
Shares of Stryker were trading at $59.32 as of July 13, 2011. Since January 1st, shares of Stryker have given investors a return of 11.1%.Average Stock Rating:
The average rating by analysts for Stryker is a Hold.Competitors:
Looking for a sympathy stock to trade or interested in the performance of other companies in the same sector? Take a look at one of Stryker's peers.- Medtronic MDT: Hold with a $0.9 recent quarter EPS
The medical products company's industry has seen price/earnings growth of 1.4% during the current fiscal year.
Finally, a description of the main business areas of the company, in case you need a little refresher: Stryker Corp. is a medical technology firm, which produces a range of products in medical implants, surgical technologies and emergency medical equipment. It is divided into two segments, which are Orthopaedic Implants and MedSurg Equipment.
Take Action:
Now that you're fully prepared, get ready to take quick action if the company reports any numbers significantly different from those listed above. Also, check back in with us after the announcement for a full recap and what-to-do-next guide.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.